Cohance Lifesciences Ltd (COHANCE) — Announcement | 3 September 2026

3 September 2026 · BSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Cohance advances ADC strategy with USD 18 million total investment in NJ Bio and Aruka Bio

🔄 What Changed

Increased ownership in NJ Bio from 56.0% to 67.3%; Aruka becomes direct subsidiary with 65% direct ownership by Cohance

🔮 What's Next

Completion expected by end of September 2026

💡 Investor Takeaway

These moves deepen Cohance's control over its ADC platform and clarify leadership focus for future growth.

Cohance Lifesciences announced two strategic transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: a USD 13 million additional investment in NJ Bio and a USD 5 million controlling investment in Aruka Bio, both funded internally. The reorganisation consolidates Aruka under Cohance with 65% direct ownership, while increasing NJ Bio stake to 67.3%, aiming to enhance commercial integration and pipeline development. Completion is expected by end-September 2026 pending approvals.

📄 View Original Announcement (PDF)

📊 Stock Analysis — COHANCE ✨ Ask AI About This

About Cohance Lifesciences Ltd (COHANCE)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹17,473.75 CrP/E: 298.5ROE: 2.7%ROCE: 3.3%

View full COHANCE stock details →

📡 Get AI alerts when COHANCE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track COHANCE — Free

💡 Ask AI about this filing

"How will the ADC integration impact Cohance's financials?""What milestones are set for Aruka's pipeline development?""How does the leadership transition affect NJ Bio's operations?"

Ask AI Free →

📊 More COHANCE filings

Announcement — 28 September 2026Cohance Lifesciences Ltd announced that its trading window closes on 1 October 2026 for insiders and...
Announcement — 21 September 2026Cohance Lifesciences announced that the USFDA inspected its API facility in Andhra Pradesh from Sept...
🟡 Board Meeting — 18 September 2026Cohance Lifesciences invested USD 10 million in newly issued Compulsorily Convertible Preferred Stoc...
🟡 Voting Results — 17 September 2026Cohance Lifesciences held its 8th Annual General Meeting on 17 September 2026 via video conference, ...
🟡 Board Meeting — 17 September 2026Cohance Lifesciences held its 8th Annual General Meeting on 17 September 2026 via video conference, ...

See all COHANCE filings →

🔥 Also filed on 3 September 2026

517554NHC Foods LtdAnnual Report HINDCOMPOSHindustan Composites LtdAnnouncement 534796JUJHAR LOGISTICS LIMITEDAnnual Report 500388Shree Krishna Paper Mills & Industries LtdAnnual Report VSTLVibhor Steel Tubes LtdInsider Trading GAUDIUMIVFGaudium IVF and Women Health LtdAnnual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when COHANCE files new disclosures

Track COHANCE filings, board meetings, and corporate actions. Free email alerts at 5 PM.